Xadago Tablet, Film Coated
Product Images NDC 27505-110

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Xadago (NDC 27505-110). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mdd Us Operations Llc, A Subsidiary Of Supernus Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Xadago 01)

Chemical structure of safinamide mesylate, the active ingredient in Xadago tablets. The diagram depicts the molecular arrangement including aromatic rings, fluorine substitution, amide, and mesylate functional groups.*

FDA Label Image

Figure 1 (Xadago 02)

A line graph showing mean change from baseline in total daily on time over 24 weeks for Xadago 50 mg/day, Xadago 100 mg/day, and placebo groups. The X-axis represents weeks from 0 to 24, and the Y-axis shows mean change from baseline values from 0.0 to 2.0 hours. Both Xadago dosage groups show an upward trend with greater mean change than placebo, with error bars indicating variability at each time point.*

FDA Label Image

Figure 2 (Xadago 03)

A cumulative percentage plot showing change from baseline to week 24 in total daily ON time (hours) for Xadago 50 mg/day, Xadago 100 mg/day, and placebo groups. The x-axis represents hours of ON time change, with increases and decreases, and the y-axis shows cumulative percentage (%) of subjects.*

FDA Label Image

Figure 3 (Xadago 04)

A line graph showing mean change from baseline in 'on' time over 24 weeks. It compares Xadago 50-100 mg/day (dashed line with crosses) and placebo (solid line with triangles). Xadago shows a higher increase in 'on' time compared to placebo, with data points at multiple weeks and error bars representing variability. Sample sizes (N) for each group at each time point are listed below the x-axis.*

FDA Label Image

Figure 4 (Xadago 05)

A cumulative percentage plot comparing the change from baseline to Week 24 in total daily "ON" time (hours) between placebo and Xadago 50-100 mg/day. The x-axis represents the change in hours, ranging from -8 to 12, while the y-axis shows cumulative percentage, ranging from 0% to 100%. Two lines illustrate the cumulative distribution for placebo and Xadago treatment groups.*

FDA Label Image

Principal Display Panel (50 mg Tablet Bottle Carton)

Packaging label for Xadago 50 mg film-coated tablets (safinamide) in a carton containing 30 tablets. The label shows the proprietary and generic names, strength, NDC 27505-110-30, distributor information (US WorldMeds, LLC), storage instructions, and barcodes. The design features a horizontal orange stripe with the strength prominently displayed.*

FDA Label Image

Principal Display Panel (100 mg Tablet Bottle Carton)

Packaging label for Xadago (safinamide) tablets 100 mg film-coated oral tablets. The label displays the product name, strength, quantity of 30 tablets, and warnings to keep out of reach of children. It shows the National Drug Code (NDC) 27505-111-30, distributor US WorldMeds, LLC, and manufacturer information under license from Newron Pharmaceutical SpA. Storage instructions and trademark details are also included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.